Efavirenz/lamivudine/tenofovir
(Redirected from
Efavirenz/lamivudine/tenofovir disoproxil
)Combination of | |
---|---|
Nucleoside reverse transcriptase inhibitor | |
Clinical data | |
Trade names | Symfi, Symfi Lo |
Other names | EFV/3TC/TDF |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a618028 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a
antiretroviral medication for the treatment of HIV/AIDS.[1][2][3] It combines efavirenz, lamivudine, and tenofovir disoproxil.[3] As of 2019[update], it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[4] It is taken by mouth.[1][2][3]
Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.
It is on the
References
- ^ a b c d "Symfi- efavirenz, lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 25 September 2021.
- ^ a b c d "Symfi Lo- efavirenz, lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 25 September 2021.
- ^ a b c d e f g h "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO). Archived from the original on October 26, 2015.
- hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". U.S. Food and Drug Administration (FDA). Archived from the original on February 27, 2016. Retrieved 13 December 2017.
- ^ "Drug Approval Package: Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 15 August 2020.
- ^ "Drug Approval Package: Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 24 November 2018. Retrieved 15 August 2020.
- ^ "Office of Generic Drugs 2020 Annual Report". U.S. Food and Drug Administration (FDA). Retrieved 12 February 2021.
- ^ "Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.
- ^ "Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.
External links
- "Efavirenz". Drug Information Portal. U.S. National Library of Medicine.
- "Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.